This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

The information a reader is about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the company or via the Product Information.

NP-AU-NA-WCNT-250004 Date of Approval July 2025.

Continue

Go back

 

Respiratory and Allergy

Oncology

GSK is focusing on cancer treatments with our first therapy for the treatment of ovarian cancer.